914637-31-3

Basic information

• Product Name: 3-Fluoro-5-methoxyphenylacetonitrile
• Synonyms: 3-Fluoro-5-Methoxybenzyl cyanide;2-(3-Fluoro-5-Methoxyphenyl)acetonitrile;3-Fluoro-5-methoxybenzyl cyanide, 3-(Cyanomethyl)-5-fluoroanisole
• CAS NO: 914637-31-3
• Molecular Formula: C₉H₈FNO
• Molecular Weight: 165.1643232
• Mol File: 914637-31-3.mol

Chemical Properties

• Boiling Point: 249℃
• Flash Point: 105℃
• Appearance: /
• Density: 1.148
• CAS DataBase Reference: 3-Fluoro-5-methoxyphenylacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluoro-5-methoxyphenylacetonitrile(914637-31-3)
• EPA Substance Registry System: 3-Fluoro-5-methoxyphenylacetonitrile(914637-31-3)

Safety Data

• RIDADR: 2810
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 914637-31-3(Hazardous Substances Data)

Usage

Chemical Properties

Colorless Liquid

Upstream product

• 1214346-07-2 1-(chloromethyl)-3-fluoro-5-methoxybenzene 
• 143-33-9 sodium cyanide 
• 202925-08-4 1-chloro-3-fluoro-5-methoxybenzene 
• 105-56-6 ethyl 2-cyanoacetate 
• 29578-39-0 1-bromo-3-fluoro-5-methoxybenzene 
• 7677-24-9 trimethylsilyl cyanide 
• 914637-29-9 1-(bromomethyl)-3-fluoro-5-methoxybenzene 
• 914637-27-7 (3-fluoro-5-methoxyphenyl)methanol 
• 176548-72-4 3-fluoro-5-methoxybenzoic acid 
• 455-40-3 3,5-difluorobenzoic acid 

Downstream Products

• 914637-33-5 2-(3-fluoro-5-methoxyphenyl)acetic acid 
• 1352306-24-1 1-(2,5-dimethoxyphenyl)-2-(3-fluoro-5-methoxyphenyl)ethanone 
• 1564226-00-1 1-(2-chlorophenyl)-8-fluoro-6-methoxy-3-methyl-3H-pyrazolo[3,4-c]cinnoline 
• 1564237-15-5 5-amino-4-(3-fluoro-5-methoxyphenyl)-1-methyl-1H-pyrazol-3-ol 
• 1564236-75-4 ethyl 2-cyano-2-(3-fluoro-5-methoxyphenyl)acetate 

Relevant articles and documents

Assembly of α-(Hetero)aryl Nitriles via Copper-Catalyzed Coupling Reactions with (Hetero)aryl Chlorides and Bromides

α-(Hetero)aryl nitriles are important structural motifs for pharmaceutical design. The known methods for direct synthesis of these compounds via coupling with (hetero)aryl halides suffer from narrow reaction scope. Herein, we report that the combination of copper salts and oxalic diamides enables the coupling of a variety of (hetero)aryl halides (Cl, Br) and ethyl cyanoacetate under mild conditions, affording α-(hetero)arylacetonitriles via one-pot decarboxylation. Additionally, the CuBr/oxalic diamide catalyzed coupling of (hetero)aryl bromides with α-alkyl-substituted ethyl cyanoacetates proceeds smoothly at 60 °C, leading to the formation of α-alkyl (hetero)arylacetonitriles after decarboxylation. The method features a general substrate scope and is compatible with various functionalities and heteroaryls.

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease

The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.

NOVEL COMPOUNDS

The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.